Even triple negative breast cancers expressing very low levels of androgen receptor may benefit from anti-androgen therapy, researchers report. “This line of work is starting to change our thinking about who and when — the timing and patient selection for anti-androgen receptor therapy in triple-negative breast cancer,” says the study’s first author.